$FBLG News

EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial

FibroBiologics Announces Preclinical Data From Its CYPS317 Program For Psoriasis Was Presented At The Society For Investigative Dermatology Meeting, May 13-15

FibroBiologics Files New Provisional Patent Application With USPTO Titled 'Oral Fibroblasts And Fibroblast-Derived Therapeutics And Delivery Systems For Same'

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

FibroBiologics Announces Strategic Expansion Of Its Fibroblast-Based Platform To Target Hantavirus

FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring

FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

Maxim Group Downgrades FibroBiologics to Hold

EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study

FibroBiologics Enters Into $6.15M Offering Of Common Stock

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

FibroBiologics Compliant with All Nasdaq Listing Requirements

Nasdaq Confirms FibroBiologics Demonstrated Compliance With All Applicable Criteria For Continued Listing

HC Wainwright & Co. Maintains Buy on FibroBiologics, Raises Price Target to $8

FibroBiologics Has Been Granted European Patent Number EP3787647 Titled "DE-DIFFERENTIATED FIBROBLAST-CONDITIONED MEDIA FOR TREATING OR PREVENTING DISC DEGENERATION".

FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity

FibroBiologics Announces Preclinical Data Supporting Potential Of Proprietary Thymic Organoid Platform To Reverse Age-Related Immune Decline By Restoring Thymic Function Lost Over Time

FibroBiologics Announces Preclinical Data Supporting Potential Of Proprietary Thymic Organoid Platform To Reverse Age-Related Immune Decline By Restoring Thymic Function Lost Over Time